For research use only
| Cat No. | ABC-SC0121 |
| Product Type | Human Cancer Stem Cells |
| Cell Type | Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Prostate |
| Disease | Prostate Cancer |
| Storage | Liquid Nitrogen |
Human (Parental) Prostate Cancer Stem Cell; Frozen Vial and Plated cells are available.
HighQC™ Human (Parental) Prostate Cancer Stem Cells are a rare and highly tumorigenic population derived from primary human prostate carcinoma tissues. Morphologically, they exhibit a small, round or slightly elongated shape. These cells represent prostate cancer stem cells (PCSCs), characterized by their self-renewal ability, long-term proliferation, and potential to generate heterogeneous tumor cell populations. These cells express key PCSC markers, including CD44 and CD133. They exhibit self-renewal, generate heterogeneous prostate cancer cell populations in vitro, and initiate tumors in xenograft models. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human (Parental) Prostate Cancer Stem Cell, Human Parental PCSC, hPara-PCSC, Human Prostate Cancer Progenitors |
| Species | Human |
| Cat.No | ABC-SC0121 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Prostate |
| Disease | Prostate Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Cancer Stem Cells |
HighQC™ Human (Parental) Prostate Cancer Stem Cells, also known as prostate tumor-initiating cells (TIC), are widely used to investigate cancer stem cell (CSC) biology, including mechanisms of dormancy, metastasis, and relapse. This Parental prostate CSC line exhibits the ability to form tumor spheroids in vitro and generate xenograft tumors in vivo, making them ideal for preclinical drug screening and enabling the evaluation of novel CSC-targeted therapies such as Wnt/β-catenin, Notch, or Hedgehog pathway inhibitors.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).